NVSNovartis PharmaceuticalsRunning, no new patients
Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Chinese Men and Postmenopausal Women With Advanced Breast Cancer
Breast Neoplasms
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 69 (final count)
- Started
- Jan 20, 2021
- Main results expected
- Jan 29, 2027
- Fully finished
- Jan 29, 2027
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Progression Free Survival (PFS)
Measured over: From the date of randomization to the date of the first documented progression or death due to any cause, up to approximately 34 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT04544189 · record last updated 2026-09-18 · checked 2026-11-09 15:47 UTC